PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy

Immune checkpoint therapy (ICT) with a monoclonal antibody (MAb) against programmed cell death protein 1 (PD-1) is a powerful clinical treatment for tumors. Cemiplimab is a human IgG4 antibody approved in 2018 and is the first MAb proven to be effective for locally advanced basal cell carcinoma. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Dan, Xu, Zepeng, Zhang, Ding, Jiang, Min, Liu, Kefang, He, Juanhua, Ma, Dongli, Ma, Xiaopeng, Tan, Shuguang, Gao, George F., Chai, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924070/
https://www.ncbi.nlm.nih.gov/pubmed/35309324
http://dx.doi.org/10.3389/fimmu.2022.826045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924070/
https://www.ncbi.nlm.nih.gov/pubmed/35309324
http://dx.doi.org/10.3389/fimmu.2022.826045

Ejemplares similares